Asabys Partners
Venture capitalMadrid · Seed–Growth · 18 people tracked
Investment thesis
Asabys focuses on pushing the boundaries of science and medicine to improve patients' lives, backing highly innovative and transformative technologies. The firm positions itself as a hands-on partner and collaborator to its portfolio companies. It integrates environmental, social, and governance considerations into its investment processes and aligns its practices with the United Nations Sustainable Development Goals. Asabys is financially backed by the EU under the EFSI established through the Investment Plan for Europe.
Source: firm website, verified Aug 3, 2026.
Team · 18 people
from the firm's website & public directories
What they invest in
from 17 of 40 portfolio companiesHealthtech ×10Medical Devices ×9Biotech ×8Deep Tech ×6AI & Machine Learning ×5Digital Health ×3Mental Health ×1Wellness & Fitness ×1
HQs:Spain×5Belgium×1France×1
Investments · 40 tracked
founders shown can be your intro pathSpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes.
BiotechDeep TechDigital HealthBarcelona, ES
Dr. Frutos(Co-founder)Dr. Vila-Perelló(CEO)
Accure Therapeutics is a research and development pharmaceutical company developing medicines to treat central nervous system (CNS) diseases.
BiotechHealthtech
R&D-driven biopharmaceutical company developing innovative medicines for central nervous system diseases
Agomab Therapeutics is a clinical-stage biopharmaceutical company developing small molecule inhibitors targeting fibro-inflammation, with a focus on treating fibrotic diseases including Fibrostenosing Crohn's Disease and Idiopathic Pulmonary Fibrosis.
BiotechMedical DevicesAntwerp, BE
Tim Knotnerus(Chief Executive Officer)
Augustine Therapeutics is a biotech company developing HDAC6-targeted therapies for peripheral neuropathies such as Charcot-Marie-Tooth disease and chemotherapy-induced peripheral neuropathy, as well as neurodegenerative disorders like ALS.
BiotechMedical Devices
HealthtechTrowbridge
Stanley Lapidus(Director)Andrew Goldman(Director)Anna Dixon(Executive Officer)Martin Munchbach(Director)Jihua Wang(Director)Joachim Rothe(Director)
Gradient develops the Gradient Denervation System, a minimally invasive, ultrasound-based catheter platform that ablates nerves around the pulmonary artery (pulmonary artery denervation) to treat patients with pulmonary hypertension, including those with pulmonary hypertension due to left heart disease.
HealthtechMedical Devices
Koa Health develops a unified digital mental health platform that delivers evidence-based treatment programs and clinical interventions.
Digital HealthHealthtechMental Health
Oliver Harrison(Chief Executive Officer)
Advancing engineered cytokines for the treatment of immune-mediated diseases.
Orikine Bio develops precision-engineered bi-specific cytokine therapies ("Foldikines") that reprogram immune signaling to treat severe autoimmune and inflammatory diseases.
BiotechDeep TechHealthtechBarcelona, ES
Larry Edwards(Chairman of the Board)
Peptomyc is a biotech company developing MYC inhibitors for cancer treatment, based on the Omomyc molecule, and is advancing them through preclinical and clinical trials.
BiotechDeep TechHealthtechMedical DevicesBarcelona, ES
Dr. Laura Soucek(Co-founder and CEO)Dr. Marie-Eve Beaulieu(Co-founder)Laura Soucek(Co-founder & CSO (former CEO))
SafeHeal develops Colovac, a colorectal anastomosis protection device designed to reduce fecal contact at the surgical site following colorectal surgery, potentially eliminating the need for diverting ostomy.
HealthtechMedical DevicesFrance, FR
Chris Richardson(Chief Executive Officer)
Sidekick Health develops a digital health platform for multi-chronic condition management and personalized care experiences, delivering patient education and lifestyle support for conditions such as IBD, rheumatoid arthritis, and dermatological disease.
Digital HealthHealthtechWellness & Fitness
INBRAIN Neuroelectronics develops graphene-based brain-computer interfaces that decode and modulate neural signals, combined with AI, to deliver real-time personalized therapy for neurological disorders such as Parkinson's disease and for brain tumor surgery.
AI & Machine LearningDeep TechMedical DevicesBarcelona, ES
Carolina Aguilar(CEO & Founder)
XR therapeutics platform company that merged with Amelia Virtual Care.
Frequently asked questions
- What stage does Asabys Partners invest at?
- Asabys Partners invests at the Seed, Series A, Series B, Series C, Growth stages.
- What sectors does Asabys Partners focus on?
- Asabys Partners focuses on Biotech, Deep Tech, Digital Health, Healthtech, Impact & Social Good, Medical Devices.
- Where is Asabys Partners located?
- Asabys Partners is headquartered in Madrid, ES.
- Does Asabys Partners lead rounds?
- Asabys Partners typically participates in rounds rather than leading them.
Media · Podcasts & interviews
featuring the teamClara Campàs comenta la misión de Asabys Partners
Crónica Global · Clara Campàs
#LifeAfterCovid: Clara Campàs (Asabys Partners), entrevista completa
Capital Cell · Clara Campàs
Co-investors · 1
Ysios Capital is a life sciences investor that finances innovative biotech companies worldwide, providing resources to develop novel therapies for indications with high unmet medical needs.
Firms observed investing alongside Asabys Partners, from public investor directories. Shared companies are the overlap with Asabys Partners's recorded portfolio.
Similar investors
Innovestor is a Nordic investment group operating across venture capital, life science, real estate, energy storage, and corporate venturing platforms, and is among the most active early-stage investors in the region.
MaRS is a Toronto-based innovation hub and accelerator that supports Canadian startups from pre-seed funding through international expansion, offering workspace, mentorship, investor and customer connections, and sector-focused programming.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
Novo Holdings is the holding and investment company that manages the assets of the Novo Nordisk Foundation, serving as controlling shareholder of Novo Nordisk and Novonesis. It invests in life science companies across all stages and manages a diversified portfolio of equities, bonds, real estate, infrastructure and private equity.
MDI Ventures is the corporate venture capital arm of Indonesia's Telkom Group, investing in technology startups and emphasizing measurable social and environmental impact alongside financial returns.